• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 4
  • Tagged with
  • 4
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Serine/arginine protein kinase (SRPK) inhibition as a potential therapeutic strategy against leukemia cells / Inibição de serine/arginine protein kinase (SRPK) como estratégia terapêutica contra linhagens leucêmicas

Siqueira, Raoni Pais 28 February 2018 (has links)
Submitted by Marco Antônio de Ramos Chagas (mchagas@ufv.br) on 2018-04-19T13:14:58Z No. of bitstreams: 1 texto completo.pdf: 2407879 bytes, checksum: 24a29868ff91347f5c8b65b662cb7870 (MD5) / Made available in DSpace on 2018-04-19T13:14:58Z (GMT). No. of bitstreams: 1 texto completo.pdf: 2407879 bytes, checksum: 24a29868ff91347f5c8b65b662cb7870 (MD5) Previous issue date: 2018-02-28 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Serine/Arginine protein kinases (SRPKs) são componentes chave da maquinaria de splicing através da regulação por fosforilação das proteínas SR, as quais são cruciais para a seleção dos sítios de splicing alternativo. Entretanto, as SRPKs são frequentemente encontradas superexpressas ou com atividade alterada em diversos tipos de cânceres, inclusive em leucemias. Dessa forma, a busca por pequenas moléculas inibidores destas quinases são de potencial interesse para o delineamento de novas estratégias terapêuticas. Nesta tese, descreve­se a avaliação da inibição farmacológica de SRPKs pelo inibidor seletivo N­(2­ (piperidin­1­il)­5­(trifluorometil)fenil)isonicotinamida (SRPIN340) sobre a viabilidade de linhagens leucêmicas linfoides e mieloides. Além de mostrar atividade citotóxica significativa, o efeito dos tratamentos na regulação da fosforilação das proteínas SR e na alteração da expressão dos genes MAP2K1, MAP2K2, VEGF e FAS foram também identificados. Além disso, a inibição farmacológica de SRPKs foi capaz de desencadear eventos precoces e tardios de apoptose. Por último, estudos de fluorescência intrínseca de triptofano, docking molecular e dinâmica molecular foram analisados a fim de se obter informações estruturais acerca do complexo SRPK/SRPIN340. No segundo estudo, é descrita a síntese de uma série de vinte e duas trifluorometil arilamidas baseadas na estrutura molecular do SRPIN340, além da avaliação dos seus efeitos antileucêmicos. Alguns dos derivados apresentaram efeitos citotóxicos superiores contra linhagens de leucemia mieloide e linfoide em comparação com o SRPIN340. Em particular, os compostos N­(2­(4­bromofenilamino)­5­(trifluorometil)fenil)­2­cloronicotinamida (24), N­(2­(4­bromofenilamino)­5­(trifluorometil)fenil)nicotinamida (30), e N­(2­(4­ bromofenilamino)­5­(trifluorometil)fenil)benzamida (36) apresentaram valores de IC 50 na faixa de 6,0 – 35,7 μM (μmol L ­1 ). Estes três compostos também foram capazes de desencadear eventos de apoptose e autofagia, além de exibir efeito sinergístico em combinação com o agente quimioterápico vincristina. Além disso, o composto 30 se mostrou mais eficiente que o SRPIN340 na diminuição da fosforilação das proteínas SR bem como na diminuição da expressão de isoformas oncogênicas dos genes MAP2K1, MAP2K2, VEGF, e RON. Tomados conjuntamente, estes resultados sugerem que inibidores de SRPKs são capazes de suprimir o crescimento celular através da regulação dos eventos de splicing e podem ser considerados como ponto de partida importante para desenvolvimento de novas estratégias terapêuticas contra leucemias e outros tipos de cânceres. / Serine/Arginine protein kinase (SRPK) are key components of the splicing machinery trough the phospho­regulation of SR Proteins, which are crucial for exon selection in the alternative splicing. However, SRPK have frequently been found overexpressed or/and with altered activity in a number of cancers, including leukemias. Thus, the discovery of small molecule inhibitors against these kinases is of potential interest to identify novel therapeutic opportunities. Here, it is described the pharmacological inhibition of SRPK by N­(2­(piperidin­1­yl)­5­ (trifluoromethyl)phenyl)isonicotinamide (SRPIN340) on the viability of lymphoid and myeloid leukemia cell lines. Along with significant cytotoxic activity, the effect of treatments in regulating the phosphorylation of the SR protein family and in altering the expression of MAP2K1, MAP2K2, VEGF and FAS genes were also assessed. Furthermore, it was found that pharmacological inhibition of SRPKs can trigger early and late events of apoptosis. Finally, intrinsic tryptophan fluorescence emission, molecular docking and molecular dynamics were analyzed to gain structural information on the SRPK/SRPIN340 complex. In a second study, it is described the synthesis of a series of twenty­two trifluoromethyl arylamides based on the SRPIN340 scaffold and the evaluation of their antileukemia effects. Some derivatives presented superior cytotoxic effects against myeloid and lymphoid leukemia cell lines compared to SRPIN340. In particular, compounds N­(2­(4­bromophenylamino)­5­(trifluoromethyl)phenyl)­2­chloronicotinamide (24), N­(2­(4­bromophenylamino)­5­(trifluoromethyl)phenyl)nicotinamide (30), and N­(2­(4­ bromophenylamino)­5­(trifluoromethyl)phenyl)benzamide (36) presented IC 50 values within the 6.0 – 35.7 μM (μmol L ­1 ) range. In addition, these three compounds were able to trigger apoptosis and autophagy, and they exhibited synergistic effects in combination with the chemotherapeutic agent vincristine. Moreover, compound 30 was more efficient than SRPIN340 in impairing the intracellular phosphorylation status of SR proteins as well as the expression of MAP2K1, MAP2K2, VEGF, and RON oncogenic isoforms in leukemia cells. Taken together, these results suggest that SRPK pharmacological inhibitors may be considered for the development of novel therapeutic strategies against leukemias and other types of cancers.
2

Stress-induced alternative splicing of Serine/Arginine-rich proteins in the moss Physcomitrella patens

Olsen, Jessica January 2011 (has links)
Plants are sessile organisms and thus more exposed to stressful environments. By changing the expression of stress related genes, plants are able to cope with stress. Alternative splicing (AS) of pre-mRNA is a major contributor to proteome diversity in eukaryotes. It has been shown that different abiotic stresses affect AS patterns, suggesting a functional role of AS in stress tolerance. The Serine/Arginine-rich proteins (SR proteins) are a conserved family of splicing regulators in eukaryotes. SR proteins are essential for AS and studies have shown that they are themselves subjects to AS after stress exposure which means that they can control their own splicing. In this study, the aim was to characterize the different SR-proteins in the SR subfamily in P. patens, analyze their phylogeny and measure the change in expression of the genes after exposure to five types of stress; osmotic, salinity, dehydration, cold and hormonal. The result showed both individual and overlapping changes in their expression profiles of the three genes. Furthermore, there was an alteration in the alternative splicing pattern for two genes during three of the stresses which resulted in intron retention and possibly a premature termination codon and subseqent non-sense mediated decay.
3

The RNA Binding Protein SRSF1 modulates Immune and Cancer pathways by regulating MyD88 transcription

Unknown Date (has links)
Serine/Arginine splicing factor 1 (SRSF1), a member of the Serine/Arginine rich (SR) RNA-binding proteins (RBPs) family, regulates mRNA biogenesis at multiple steps and is deregulated in cancer and autoimmune diseases. Preliminary studies show that members of the SR protein family play a role in cellular transcription. We investigated SRSF1’s role in cellular gene transcription utilizing time-course RNA-Seq and nuclear run-on assays, validating a subset of genes transcriptionally regulated following SRSF1 overexpression. Pathway analysis showed that genes in the TNF/IL17 pathways were enriched in this dataset. Furthermore, we showed that MyD88, a strong activator of TNF transcription through transcription factors NF-κB and AP-1, is a primary target of SRSF1’s transcriptional activity. We propose that SRSF1 activates the transcription factors NF-κB and AP-1 through MyD88 pathway. SRSF1 overexpression regulates several genes that are deregulated in malignancies and immune disease, suggesting a role for SRSF1’s transcriptional activity in oncogenesis and immune response regulation. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2020. / FAU Electronic Theses and Dissertations Collection
4

Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion / 偽エクソン生成を標的とした嚢胞性線維症に対する個別化医療

Shibata, Saiko 23 March 2021 (has links)
京都大学 / 新制・課程博士 / 博士(医学) / 甲第23065号 / 医博第4692号 / 新制||医||1049(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 村川 泰裕, 教授 平井 豊博, 教授 小川 誠司 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Page generated in 0.0802 seconds